Nuvalent (NUVL) Cash from Financing Activities (2020 - 2026)
Nuvalent's (NUVL) quarterly Cash from Financing Activities came in at $9.8 million in Q1 2026, up 115.5% YoY from $4.5 million in Q1 2025, and down 98.04% on a QoQ basis from $500.3 million in Q4 2025.
Analysis
Nuvalent (NUVL) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Cash from Financing Activities data on file, last reported at $9.8 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 115.5% year-over-year to $9.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $520.6 million (down 8.26% YoY) and the FY2025 annual result came in at $515.3 million, down 9.41% from the prior year.
- Cash from Financing Activities eased to $9.8 million in Q1 2026, from $500.3 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $550.3 million in Q3 2024 to a low of -$768000.0 in Q1 2022.
- A 5-year average of $98.8 million and a median of $4.8 million in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 107.68% — and 2024, when it jumped 35311.76%.
- Tracing NUVL's Cash from Financing Activities over 5 years: stood at $248.7 million in 2022, then jumped by 34.08% to $333.4 million in 2023, then plunged by 97.45% to $8.5 million in 2024, then surged by 5791.0% to $500.3 million in 2025, then sank by 98.04% to $9.8 million in 2026.
- The last three Cash from Financing Activities figures came in at $9.8 million (Q1 2026), $500.3 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 9.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 9.80 Mn |
| Dec 31, 2025 | 500.26 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 5.76 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Dec 31, 2024 | 8.49 Mn |
| Sep 30, 2024 | 550.27 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Mar 31, 2024 | 5.99 Mn |
| Dec 31, 2023 | 333.42 Mn |
| Sep 30, 2023 | 2.14 Mn |
| Jun 30, 2023 | 1.30 Mn |
| Mar 31, 2023 | -17,000.00 |
| Dec 31, 2022 | 248.67 Mn |
| Sep 30, 2022 | 1.01 Mn |
| Jun 30, 2022 | 5,000.00 |
| Mar 31, 2022 | -768,000.00 |
| Dec 31, 2021 | -944,000.00 |
| Sep 30, 2021 | 174.93 Mn |
| Jun 30, 2021 | 134.23 Mn |